62results about How to "Enhance anti-tumor immune response" patented technology

The invention relates to a preparation method and application of an anti-tumor vaccine based on cell microvesicles and aims to effectively solve problems in preparation of anti-tumor vaccines high inyield, good in universality, strong in killing effect on tumor cells and capable of controlling tumors by improving tumor microenvironments, repairing an immune system and enhancing anti-tumor immuneresponse of organisms. The preparation method comprises the following steps: preparing tumor cell microvesicles loaded with immunomodulators and connecting the surfaces of the microvesicles with adjuvant-loaded liposome to stably form the anti-tumor vaccine. The prepared anti-tumor vaccine is high in yield, good in universality, strong in killing effect on tumor cells and capable of improving tumor microenvironments, repairing an immune system and enhancing anti-tumor immune response of organisms; the method is simple in process and high in efficiency; and the prepared microvesicles are derived from cells, are sufficient in quantity and wide in source, are easy for large-scale production, improve the bioavailability of adjuvants, are effectively applicable to preparation of anti-tumor vaccines based on the cell microvesicles, and can be applied to prevention and treatment of different types of tumors.

The invention provides an organic AIE photosensitive probe with mitochondrial targeting and a preparation method and application thereof, and belongs to the technical field of antitumor drugs. The organic AIE photosensitive probe with mitochondrial targeting has a structure as shown in the following formula I in the specification. According to the organic AIE photosensitive probe, mitochondrial ROS oxidative stress is triggered, a large amount of calreticulin translocation is induced to be generated, the immunogenicity of tumor cells is effectively improved, and lasting anti-tumor immune response of an organism is triggered. Therefore, the organic AIE photosensitive probe is applied to preparation of drugs for tumor cell immune response or preparation of reagents for triggering the mitochondrial ROS oxidative stress and inducing generation of calreticulin transposition.

The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and / or CD8 T cells.

The invention discloses a chimeric antigen receptor T lymphocyte and an application thereof to preparation of a product for treating solid tumors. A chimeric antigen receptor in the chimeric antigen receptor T lymphocyte sequentially comprises a human CD8 lead peptide, an anti-Siglec-15 single-chain antibody, a human CD8 hinge transmembrane region, a human 4-1BB intracellular region, a human CD3 zeta intracellular region, a self-cleavage peptide, a CSF2Ra signal peptide, an EGFRt protein, a self-cleavage peptide and a human CD27. Experiments prove that the chimeric antigen receptor T lymphocyte provided by the invention highly expresses IFN gamma and CD107a, has a strong killing function on Siglec-15 positive tumor cells, and has killing efficiency of more than 80% under the condition thatthe effect-target ratio is 1: 1. A tumor transplantation model experiment shows that the chimeric antigen receptor T lymphocyte also has a strong killing function on Siglec-15 positive tumor cells inan animal body.

The invention relates to an oncolytic virus vaccine and adoptive immune cell combination therapy. Specifically, the present disclosure relates to a modified matrix protein (M) of recombinant oncolyticrod-like virus, an oncolytic virus, an oncolytic virus vaccine, and combination therapy of the oncolytic virus vaccine with endogenous and adoptive immune cells. The present disclosure also providesantineoplastic preparations, including independent administration for oncolytic virus, oncolytic virus vaccine, and multiple-route and combination administration therapies. The present disclosure alsoprovides methods and strategies of the combination therapy for treating cancers, as well as a method for preparing an oncolytic virus vaccine and a tumor antigen specific central memory CD8+T cell population. According to the combination therapy provided by the invention, all potentials of adoptive immune cells and endogenous T cells aiming at various tumor-associated antigens can be developed, so that primary and secondary metastatic primary tumors are effectively eliminated, immune escape is prevented, long-time memory protection is generated, and the effect of radically treating tumors isachieved.

The invention relates to the technical field of biomedicine, in particular to an EGFP-Wnt2 fusion protein antigen, a Wnt2 monoclonal antibody and an application of a Wnt2 monoclonal antibody. The EGFP-Wnt2 fusion protein antigen is mainly a fusion protein of EGFP and a full-length amino acid sequence of a humanized Wnt2 signal-erasing peptide. The EGFP-Wnt2 fusion protein antigen comprises an EGFPamino acid sequence, a TEV restriction enzyme cutting site and a FLAG tag sequence, and the Wnt2 signal-erasing peptide full-length amino acid sequence, a 6* His tag sequence and an anti-Wnt2 monoclonal antibody can be used for inhibiting immune escape and growth of tumor cells. When the Wnt2 monoclonal antibody disclosed by the invention is combined with the human Wnt2 antigen secreted by cells,the promotion of the cell on the formation of an inhibitory immune microenvironment in a tumor is antagonized, and the immune escape and growth of the tumor cell are inhibited. The Wnt2 monoclonal antibody provided by the invention can be used in immune treatment of solid tumors such as esophageal squamous carcinoma, gastric cancer, pancreatic cancer, colorectal colon cancer, lung cancer, breastcancer, glioma, liver cancer and the like.

The invention relates to the field of biotechnologies, and discloses an antitumor composition, a co-expression vector for the same and application of the antitumor composition. The antitumor composition, the co-expression vector and the application have the advantages that combination of 1L-36 gamma and PD-1 (programmed death-1) / PD-L1 (programmed death-ligand 1) signal blocking agents on tumor sites is demonstrated, antitumor immune response in tumor micro-environments can be effectively promoted, and tumor growth can be obviously inhibited; the lifetime of tumor-bearing mice can be greatly prolonged, novel and effective tumor immunotherapy is created, and theoretical and method foundations can be laid for further developing corresponding tumor immunological preparations.

The invention relates to an immune cell modified by a suppressor protein blocking type chimeric antigen receptor and application of the immune cell. The immune cell modified by the suppressor protein blocking type chimeric antigen receptor is used for a medicine for treating malignant tumors, and the suppressor protein and the chimeric antigen receptor are co-expressed in the immune cell; the nucleotide sequence of the suppressor protein is as shown in SEQ ID NO: 3, and the protein sequence is as shown in SEQ ID NO: 4; and the nucleotide sequence for blocking co-expression of the suppressor protein and the chimeric antigen receptor is as shown in SEQ ID NO: 5, and the protein sequence is as shown in SEQ ID NO: 6. From the perspective of blocking transduction of a negative regulation signal of the immune cell, the CAR-T cell expresses the suppressor protein, the transmission of the negative regulation signal is weakened / blocked, and the anti-tumor activity of the CAR-T cell is enhanced; and the anti-tumor immune response can be enhanced without being combined with an immune checkpoint antibody drug, the drug cost is reduced, the dosage can be accurately determined, and the curative effect is exact and remarkable.

The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.

The invention relates to a preparation method of a near-infrared response nanocage and application of the near-infrared response nanocage in tumor immune combined therapy. The preparation method of the near-infrared response nanocage comprises the four steps of preparing AuNC, preparing AuNC-coated mSiO2, preparing ASP and preparing an ASP intersection V. The near-infrared response nanocage has the advantages of good biocompatibility, safety, near-infrared region photothermal conversion, high drug loading capacity and the like. The drug-loaded nanocage can effectively deliver drugs into tumor cells and convert light energy into heat energy, light heat and a BRAF inhibitor are combined to inhibit tumor growth, induce immunogenic necrosis of the tumor cells, promote release of tumor-related antigens and generate systematic anti-tumor immune response, and the drug-loaded nanocage cooperates with an anti-PD-1 antibody to inhibit tumor growth. According to the gold nanocage, MAPK molecular targeting and anti-PD-1 immune combined treatment is realized, and a new strategy is provided for tumor treatment.